DHFR tunable protein regulation
The present invention is related to compositions and methods for the regulated and controlled expression of proteins.
1. A biocircuit system comprising at least one effector module, said effector module comprising
(a) a stimulus response element (SRE) and
(b) at least one payload, said payload comprising a protein of interest which is fused to said SRE, wherein said SRE comprises a destabilizing domain (DD), said DD comprising a human dihydrofolate reductase (hDHFR) mutant selected from the group consisting of a hDHFR comprising the amino acid sequence of SEQ ID NO. 6445; a hDHFR comprising the amino acid sequence of SEQ ID NO. 6447; a hDHFR comprising the amino acid sequence of SEQ ID NO. 6451; a hDHFR comprising the amino acid sequence of SEQ ID NO. 6452; a hDHFR comprising the amino acid sequence of SEQ ID NO. 6453; a hDHFR comprising the amino acid sequence of SEQ ID NO. 6454; and a hDHFR comprising the amino acid sequence of SEQ ID NO. 6469.
2. The biocircuit system of claim 1 , wherein the effector module is responsive to one or more stimuli, and wherein said one or more stimuli is Trimethoprim (TMP) or Methotrexate (MTX).
3. The biocircuit system of claim 1 , wherein the payload is an immunotherapeutic agent.
4. The biocircuit system of claim 3 , wherein the immunotherapeutic agent is a cytokine, a cytokine-cytokine receptor fusion protein, a chimeric antigen receptor (CAR), or combinations thereof.
5. The biocircuit system of claim 4 , wherein the immunotherapeutic agent is a chimeric antigen receptor (CAR) that comprises
(a) an extracellular target moiety;
(b) a transmembrane domain;
(c) an intracellular signaling domain; and
(d) optionally, one or more co-stimulatory domains.
6. The biocircuit system of claim 5 , wherein the extracellular target moiety is a scFv derived from an antibody that specifically binds a CD19 antigen.
7. The biocircuit system of claim 3 , wherein the immunotherapeutic agent is a cytokine.
8. The biocircuit system of claim 7 , wherein the cytokine is an interleukin, an interferon, a tumor necrosis factor, a transforming growth factor B, a CC chemokine, a CXC chemokine, a CX3C chemokine or a growth factor.
9. An effector module comprising a hDHFR-derived SRE fused to a payload, wherein the hDHFR-derived SRE is a hDHFR mutant selected from the group consisting of a hDHFR comprising the amino acid sequence of SEQ ID NO. 6445; a hDHFR comprising the amino acid sequence of SEQ ID NO. 6447; a hDHFR comprising the amino acid sequence of SEQ ID NO. 6451; a hDHFR comprising the amino acid sequence of SEQ ID NO. 6452; a hDHFR comprising the amino acid sequence of SEQ ID NO. 6453; a hDHFR comprising the amino acid sequence of SEQ ID NO. 6454; and a hDHFR comprising the amino acid sequence of SEQ ID NO. 6469.
10. The effector module of claim 9 , wherein the payload is a natural protein or a variant thereof or a therapeutic agent.
11. The effector module of claim 10 , further comprising a signal peptide, a regulatory sequence, a linker, a label, and/or a protein cleavage site.
12. A polynucleotide encoding a biocircuit of claim 1 .
13. The polynucleotide of claim 12 , wherein the polynucleotide encodes at least one additional feature selected from a promoter, a linker, a signal peptide, a tag, a cleavage site and a targeting peptide.
14. A vector comprising a polynucleotide of claim 12 .
15. The vector of claim 14 , wherein the vector is a viral vector, or a plasmid.
16. The vector of claim 15 , wherein the vector is a viral vector and said viral vector is a retroviral vector, a lentiviral vector, a gamma retroviral vector, a recombinant AAV vector, an adeno viral vector, or an oncolytic viral vector.
17. An isolated immune cell for adoptive cell transfer (ACT), which expresses the biocircuit of claim 1 .
18. The isolated immune cell of claim 17 , wherein the immune cell is a CD8+ T cell, a CD4+ T cell, a helper T cell, a natural killer (NK) cell, a NKT cell, a cytotoxic T lymphocyte (CTL), a tumor infiltrating lymphocyte (TIL), a memory T cell, a regulatory T (Treg) cell, a cytokine-induced killer (CIK) cell, a dendritic cell or a mixture thereof.
19. A pharmaceutical composition comprising the biocircuit of claim 1 and a pharmaceutically acceptable excipient.
20. An isolated immune cell for adoptive cell transfer (ACT) that expresses the polynucleotide of claim 12 .
21. The isolated immune cell of claim 20 , wherein the immune cell is a CD8+ T cell, a CD4+ T cell, a helper T cell, a natural killer (NK) cell, a NKT cell, a cytotoxic T lymphocyte (CTL), a tumor infiltrating lymphocyte (TIL), a memory T cell, a regulatory T (Treg) cell, a cytokine-induced killer (CIK) cell, a dendritic cell or a mixture thereof.
22. An isolated immune cell for adoptive cell transfer (ACT) that is infected or transfected with the vector of claim 14 .
23. A pharmaceutical composition comprising the polynucleotide of claim 12 , and a pharmaceutically acceptable excipient.
24. A pharmaceutical composition comprising the immune cell of claim 20 , and a pharmaceutically acceptable excipient.
25. A polynucleotide encoding the effector module of claim 9 .
26. An isolated immune cell for adoptive cell transfer (ACT), which expresses the effector module of claim 9 .
27. A pharmaceutical composition comprising the effector module of claim 9 , and a pharmaceutically acceptable excipient.
28. The effector module of claim 10 , wherein the natural protein or variant thereof is a fusion polypeptide, or an antibody or a fragment thereof.
29. The effector module of claim 10 , wherein the therapeutic agent is an immunotherapeutic agent, or a gene therapy agent.